ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

RENE Reneuron Group Plc

3.05
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.05 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 530k -5.41M -0.0946 -0.32 1.74M

ReNeuron Group plc Block Listing Review and Total Voting Rights (1143Y)

01/03/2017 7:00am

UK Regulatory


Reneuron (LSE:RENE)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Reneuron Charts.

TIDMRENE

RNS Number : 1143Y

ReNeuron Group plc

01 March 2017

 
 1 March 2017   AIM: RENE 
 

ReNeuron Group plc

("ReNeuron" or "the Company")

Block Listing Review and Total Voting Rights

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

 
 Name:                                ReNeuron Group plc 
-----------------------------------  ----------------------- 
 Name of Scheme:                      ReNeuron Share Option 
                                       Schemes 
-----------------------------------  ----------------------- 
 Period of Return:                    From 22 September 2016 
                                       to 28 February 2017 
-----------------------------------  ----------------------- 
 Balance of unallotted                90,282,511 Ordinary 
  securities under scheme(s)           Shares (of 1p each) 
  from previous return: 
-----------------------------------  ----------------------- 
 Plus: The amount by                  N/A 
  which the block scheme(s) 
  has been increased 
  since the date of the 
  last Review (if any 
  increase has been applied 
  for): 
-----------------------------------  ----------------------- 
 Less: Number of securities 
  issued/allotted under                 N/A 
  scheme(s) during period 
-----------------------------------  ----------------------- 
 Equals: Balance under                90,282,511 Ordinary 
  scheme(s) not yet issued/allotted    Shares 
  at end of period: 
-----------------------------------  ----------------------- 
 Number and class of                  2,000,000 Ordinary 
  securities originally                Shares on 13 May 2010 
  admitted and the date 
  of admission: 
-----------------------------------  ----------------------- 
 
 
 

Total Voting Rights

The Company has 3,164,618,541 ordinary shares in issue, all with voting rights. The Company holds no ordinary shares in treasury. The figure of 3,164,618,541 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

ENDS

ENQUIRIES:

 
ReNeuron                                                            +44 (0)20 3819 8400 
Olav Hellebø, Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
Buchanan                                                            +44 (0) 20 7466 5000 
Mark Court, Sophie Cowles, Stephanie Watson 
Stifel Nicolaus Europe Limited                                      +44 (0) 20 7710 7600 
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker) 
 

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCOKFDNABKDFBB

(END) Dow Jones Newswires

March 01, 2017 02:00 ET (07:00 GMT)

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart

Your Recent History

Delayed Upgrade Clock